# Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

> **NCT00275067** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Northwestern University** · enrollment: 50 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** arsenic trioxide
- **DRUG:** temozolomide
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00275067
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-05
- **Primary completion:** 2021-05
- **Final completion:** 2021-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275067, "Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00275067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*